Evidence map›Paper›PMID 38357261›Full record

ArticleMolecular syndromology2024

Nahid Vafaei, Ali Mohebbi, Zahra Rezaei, Morteza Heidari, Sareh Hosseinpour, Ali Zare Dehnavi, Azin Ghamari, Masoud Salehipour, Ali Rabbani, Nejat Mahdieh and 1 more

Open access · greenAbstract read
In one paragraph

Article in Molecular syndromology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Nahid VafaeiGrowth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Ali MohebbiGrowth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Zahra RezaeiPediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Morteza HeidariPediatric Neurology Division, Children's Medical Center, Pediatrics Center of Excellence, Myelin Disorders Clinic, Tehran University of Medical Sciences, Tehran, Iran.
Sareh HosseinpourPediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Ali Zare DehnaviPediatrics Center of Excellence, Department of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Azin GhamariGrowth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Masoud SalehipourDepartment of Biology, Parand Branch, Islamic Azad University, Parand, Iran.
Ali RabbaniGrowth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Nejat MahdiehGrowth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mahmoud Reza AshrafiGrowth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRChildren's Medical Center · IRIran University of Medical Sciences · IRIslamic Azad University of Parand · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: This investigation was conducted as a cross-sectional study in a tertiary referral hospital, Children's Medical Center, Pediatrics Center of Excellence. Clinical presentations and pedigrees were documented. Patients with cerebellar ataxia were enrolled in this study. Next-generation sequencing was applied to confirm the diagnosis. Segregation and bioinformatics analyses were also done for the variants using Sanger sequencing. Results: Forty-five patients were included in our study. The mean age of onset was 104 (+55.60) months (minimum = 31 months, maximum = 216 months). The majority of cases (73.3%) were born to consanguineous parents and only 1 patient (2.2%) had an affected sibling. Of the 45 patients, only 1 patient with a novel pathogenic variant (c.1425_1425+1delinsAT, p.A476Cfs*15) in the Discussion: The main strength of current study is the relatively large sample size. Besides, a novel pathogenic variant could be important toward the diagnosis and management of this condition. With significant advances in various therapies, early diagnosis could improve the treatments using personalized-based medicine.

Indexed as

Autosomal recessive cerebellar ataxiaNeuronal ceroid lipofuscinosis 2 diseasePathogenic variantPediatricsTPP1

Identifiers

PMID38357261
PMCPMC10862320
OpenAlexW4387664664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.